"10.1371_journal.pone.0055753","plos one","2013-02-07T00:00:00Z","Anna Rita Zuena; Chiara Giuli; Aldina Venerosi Pesciolini; Antonella Tramutola; Maria Antonietta Ajmone-Cat; Carlo Cinque; Giovanni Sebastiano Alemà; Angela Giovine; Gianfranco Peluso; Luisa Minghetti; Raffaella Nicolai; Gemma Calamandrei; Paola Casolini","Department of Physiology and Pharmacology Vittorio Erspamer, I Faculty of Medicine, Sapienza University of Rome, Rome, Italy; Section of Neurotoxicology & Neuroendocrinology, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy; Section of Experimental Neurology, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy; Therapeutic Area Life Cycle Management, Corporate R&D Sigma-Tau S.p.A., Pomezia, Rome, Italy; Institute of Biochemistry of Proteins, CNR, Naples, Italy","Conceived and designed the experiments: GC PC AVP. Performed the experiments: ARZ CG AVP AT MAAC CC AG GP. Analyzed the data: ARZ CG AVP GSA LM RN GC PC. Wrote the paper: GC PC LM RN.","Doctor Raffaella Nicolai is employed at Sigma-tau S.p.A. as Medical Research Senior Advisor; Raffaella Nicolai and Paola Casolini have been designated among inventors in the following European patent application: 11137170.3-2112 Compound useful for preventing cognitive deficit disorders in a new born from HIV-seropositive pregnant female who is on treatment with azidothymidine. Part of this study has been financially supported by Sigma Tau-IFR S.p.A., Italy that has synthesized and provided L-acetylcarnitine. Sigma-tau is an Italian pharmaceutical company involved in research on carnitine system which produces and sells carnitine as drugs. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. There are no other competing interests to declare.","2013","02","Anna Rita Zuena","ARZ",13,TRUE,3,8,8,4,TRUE,TRUE,FALSE,0,NA,FALSE
